Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Lexeo Therapeutics, Inc.

35 indications, side-by-side phase, drug & LoA

$4.37

+0.17 (+4.05%)

D 34Pipeline Score Overvalued Biotech · Commercial
Market Cap
401.25 M
EPS
-1.45
P/E Ratio
-
Value Trade
2.84 M
SEC Financials
Q1 2026

  • Dilution Risk

    5%

  • R&D Expenses

    15.70 M

  • Operating CF

    -21.14 M

  • Total Assets

    250.36 M

  • Total Liabilities

    18.86 M

  • Equity

    231.50 M

  • D/E Ratio

    12,345

-5.55 %
Week
-19.53 %
1 Month
-17.85 %
3 Month
-42.26 %
6 Month
-46.21 %
5 Year
-46.21 %
All Time
Cash Data
Healthy

  • Cash Position

    193.04 M

  • Monthly Burn

    7.05 M

  • Runway

    26.4 mo

  • Burn Trend

    Stable

  • SEC Filing

    May 11, 2026
Overview
Volume
625.04 K
52 Week Range
2.51 - 10.99
% held by Insiders
21.46 %
% held by Institutions
100.12 %
Enterprise Value
215.57 M
Total Shares
78.53 M
Short %
17.97 %
Float Shares
76.64 M
Company Description
HQ: 345 PARK AVENUE SOUTH, NEW YOR...
Employees:59
https://www.lexeotx.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
Phase 1/II data readout example
LX2020 PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM)
Phase 1
—
Gene Therapies
Cardiovascular System
LX2020 PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM)
Phase 1
—
Gene Therapies
Cardiovascular System
LX2020 PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM)
Phase 1
—
Gene Therapies
Cardiovascular System
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
D34
Pipeline Score
$43M
Pipeline Value
Overvalued
Valuation Signal
1
Drugs Scored
0.4x
rNPV / MCap
Top 45%
Micro Cap
(rank 499 of 905)
Percentile Rank
Lexeo Therapeutics, Inc. faces pipeline headwinds (34/100), with $107M risk-adjusted pipeline value, led by LX1001 in Alzheimer Disease (Phase 1).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
LX1001
Monoclonal antibody		Alzheimer DiseasePhase 1NCT0540033010% $107M ACTIVE NOT_RECRUITING 25 STALLED D (23) Nov 1, 2028MODERATE_RISKLOW
May 26, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
LX2006
Friedreich ataxia
Phase 1/2
2025-07-08
LX2006
Friedreich ataxia
Phase 1/2
2025-07-08
LX2006
Friedreich ataxia
Phase 1/2
2025-07-08
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in LXEO
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
LXEO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
LXEO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
LXEO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
LXEO Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
LXEO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-06-18 0.00 0 - - - - - -
2026-06-18 0.00 0 - - - - - -
2026-06-18 0.00 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Lexeo Therapeutics, Inc. (LXEO) News & Alerts
-
Sunday, June 14, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How LXEO ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Arrhythmogenic Right Ventricular Cardiomyopathy #1 of 1 PHASE 1 LX2020
—
 $1.2B 0.89 LEADER
Genetic Cardiomyopathy #1 of 1 PHASE 1 LX2020
—
—0.89 LEADER
Cardiomyopathy #7 of 13 PHASE 1 Low dose LX2006 + Mid Dose LX2006
BMY CYTK LXRX
$0.4B 0.86 FOLLOWER
Alzheimer's Disease #23 of 24 PHASE 1 LX1001
BMY LLY BIIB
$6.49B 0.85 FOLLOWER
Rare Neurological Disorders #38 of 46 PHASE 1 Low dose LX2006 + Mid Dose LX2006
IONS BIIB SRPT
$139.4B 0.83 FOLLOWER